Orphan Drug Act

 Institute of Pharmaceutical Sciences, SAGE University, Indore (M.P.)

 

                   

Stimulating drug production for rare diseases that affect the lower human population is the main concept of implementing the orphan drug act.

---

Mr. Jinendra Sardiya 

Assistant Professor                               

 Institute of Pharmaceutical Sciences, SAGE University, Indore (M.P.)

---

Definition

The Orphan Drug Act of 1983 is a law passed in the United States to facilitate development of orphan drugs—drugs for rare diseases such as Huntington's disease, myoclonus, ALS, Tourette syndrome and muscular dystrophy which affect small numbers of individuals residing in the United States.

Congress passed the Orphan Drug Act of 1983 to stimulate the development of drugs for rare diseases.1 Prior to passage of this historic legislation, private industry had little incentive to invest money in the development of treatments for small patient populations, because the drugs were expected to be unprofitable. The law provides three incentives: (1) 7-year market exclusivity to sponsors2 of approved orphan products, (2) a tax credit of 50 percent of the cost of conducting human clinical trials, and (3) Federal research grants for clinical testing of new therapies to treat and/or diagnose rare diseases. In 1997, Congress created an additional incentive when it granted companies developing orphan products an exemption from the usual drug application or “user” fees charged by the Food and Drug Administration (FDA). In fiscal year 2001, these fees will total almost $500,000. Companies also may be eligible for faster review of their applications for marketing approval if their products treat a life-threatening illness. Many orphan drugs treat a serious or life-threatening disease. Congress amended the Act in 1984, 1985, and 1988. The 1984 amendment defined a rare disease as a condition affecting fewer than 200,000 people in the United States. The threshold was an arbitrary ceiling based on the estimated prevalence of narcolepsy and multiple sclerosis. The 1985 amendment extended marketing exclusivity to patentable as well as unpatentable drugs, and the 1988 amendment required sponsors to apply for orphan designation before submitting an application for marketing approval. The FDA administers the Orphan Drug Act and reviews applications for orphan designations. Within FDA, the Office of Orphan Products Development awards designations and administers the small grants program, which is expected to total 1 The term “drug” refers to chemical entities and biological products used for the purpose of medical therapy or diagnosis. We use the terms “drug” and “product” interchangeably in this report. 2 Since most sponsors of orphan products are pharmaceutical and biotechnology companies, we use the terms “sponsor” and “company” interchangeably in this report. The Orphan Drug Act - Implementation and Impact 4 OEI-09-00-00380 $12.5 million in fiscal year 2001. The grants support clinical trials on the safety and effectiveness of products for rare diseases. The Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) review applications for marketing approval.

Insufficient pills for such illnesses and situations have not begun to advance; Drugs for those illnesses and situations are typically mentioned as "orphan pills".

Since only a few populace is stricken by any uncommon disorder or situation, a pharmaceutical organization that develops an orphan drug can also additionally majorly anticipate the drug to generate small income in evaluation to the fee of growing the drug to incur a monetary loss.

It is a different factor to accept as accurate that a number of orphan pills will no longer be advanced until modifications are made inside the relevant federal legal guidelines to lessen the prices of growing such drugs and to offer monetary incentives to expand such pills.

It is within the public hobby to provide such modifications and incentives for improving orphan pills.

Criteria

1.             The drug will be meant to be used in an extraordinary disorder or situation.

2.             Proper documentation or incidence facts ought to show that the meant situation is uncommon Proper documentation or prevalence data must prove that the intended condition is rare.

3.             There ought to be a systematic cause organizing a medically practicable foundation for the usage of the product for the uncommon situation RARE DISEASE

An uncommon disorder is any disorder that impacts a small percentage of the populace.

In a few components of the world, an orphan disorder is an extraordinary disorder whose rarity manner there may be a loss of a marketplace big sufficient to advantage assist and sources for coming across remedies for it, besides via way of means of the authorities granting economically high-quality situations to developing and promoting such remedies.

Orphan pills are ones so created or sold. The most uncommon illnesses are genetic and hence are gifted throughout the person's complete life, despite the fact that signs and symptoms do now no longer seem right away.

Many uncommon illnesses seem early in life, and approximately 30% of youngsters with uncommon illnesses will die earlier than attaining their 5th birthdays.

With the best 4 identified sufferers in 27 years, ribose-5-phosphate isomerase deficiency is taken into consideration as the rarest recognized genetic disorder.

 Definitions of Uncommon Disorder in Exclusive Countries

Aspect	Essential Drugs	Orphan Drugs
Year Established	1977Worldwide	1983 USA 2000 EU
Primary Focus	Public health	Individual Patient
Established by	WHO and Member states	USA, EU, Japan, Australia
Criteria	Drug Driven	Disease driven
Policies aimed to provide	Established medicines	New medicines to yet untreated patients
Economics	Cost-effective, Sustainable, and affordable access	High prices per patient

 

Rare illnesses are serious, frequent, continual, and revolutionary illnesses.

For many uncommon illnesses, symptoms and symptoms can be discovered at the start or in childhood, as is the case of proximal spinal muscular atrophy, neurofibromatosis, osteogenesis imperfect, chondrodysplasia, or Ret syndrome.

However, over 50% of uncommon illnesses seem at some point in adulthood, these types of Huntington's illnesses, Crohn's disorder, Charcot-Marie-Tooth disorder, amyotrophic lateral sclerosis, Kaposi's sarcoma, or thyroid cancer.

Global Statistics of Orphan Drugs

As of 2014, there have been more than 281 advertised orphan pills and extra than forty orphan-certain pills in scientific trials.

More than 60% of orphan pills have been biologics.

The U.S. ruled out improvements in orphan pills, with extra than 30 scientific trials, observed via way of means in Europe.

Cancer remedies changed into an indication in extra than 30% of orphan drug trials.

Number of orphan pills in scientific trials: 600 Number of orphan pills in Phase-2 Trial: 231

Number of orphan pills in U.S. scientific trials: 350 within side the pipeline from studies until registration.

Companies Involved in the Manufacture of Orphan Drugs

1.       Celegene

2.       Johnson & Johnson

3.       Roche

4.       Novartis

5.       Takeda

6.       Abbevie

7.       Sanofi

8.       Vertex Pharmaceuticals

9.       Alexion Pharmaceuticals

10.   Pfizer

11.   Amgen

12.   Jiangsu Hengrui Medicine

13.   Astra Zeneca

14.   BioMarin Pharmaceutical

15.   Biogen

16.   Incyte

17.   Bristol-Myers Squibb

18.   Eisai

19.   CSL

20.   Syros Pharmaceuticals

Few Orphan Drugs Examples

1. Eloctate

MFG AT: Bioverativ, a Sanofi Company

USE: Acute Haemophilia-A

2. Hemin (Brand name: Panhematin)

MFG AT: Abbott Laboratories

USE: Acute intermittent porphyria (AIP)

3. Octreotide (Brand name: Sandostatin LAR)

MFG AT: Novartis Pharmaceuticals

USE: Acromegaly

4. Edaravone (Brand name: Radicava)

MFG AT: Mitsubishi Tanabe Pharma Corporation

USE: Amyotrophic lateral sclerosis (ALS).

5. Porfimer sodium (Brand name: Photofri)

MFG AT: Pinnacle Biologics Inc

USE: Barrett's esophagus

6. Mifepristone (Brand name: Korlym)

MFG AT: Corcept Therapeutics, Inc

USE: Cushing's syndrome

7. Infliximab (Brand name: Remicade)

MFG AT: Centocor, Inc

USE: PTC Therapeutics

8. Deflazacort (Brand name: Emflaza)

MFG AT: Novartis Pharmaceuticals

USE: Crohn's disease

9. Imatinib mesylate (Brand name: Gleevec®)

MFG AT: Duchenne muscular dystrophy (DMD)

USE: Gastrointestinal